Literature DB >> 17958335

Effects of vehicles and enhancers on transdermal delivery of clebopride.

Yun-Seok Rhee1, Jai-Yong Huh, Chun-Woong Park, Tae-Young Nam, Koog-Ryul Yoon, Sang-Cheol Chi, Eun-Seok Park.   

Abstract

The effects of vehicles and penetration enhancers on the skin permeation of clebopride were evaluated using Franz type diffusion cells fitted with excised rat dorsal skins. The binary vehicle system, diethylene glycol monoethyl ether/isopropyl myristate (40/60, w/w), significantly enhanced the skin permeation rate of clebopride. The skin permeation enhancers, oleic acid and ethanol when used in the binary vehicle system, resulted in relatively high clebopride skin permeation rates. A gel formulation consisting of 1.5% (w/w) clebopride, 5% (w/w) oleic acid, and 7% (w/w) gelling agent with the binary vehicle system resulted in a permeation rate of 28.90 microg/cm2/h. Overall, these results highlight the potential of clebopride formulation for the transdermal route.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17958335     DOI: 10.1007/bf02980252

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  4 in total

1.  Effects of solvent deposited enhancers on transdermal permeation and their relationship with Emax.

Authors:  Sarah A Ibrahim; S Kevin Li
Journal:  J Control Release       Date:  2009-02-06       Impact factor: 9.776

Review 2.  Skin Penetration and Permeation Properties of Transcutol®-Neat or Diluted Mixtures.

Authors:  David W Osborne; Jasmine Musakhanian
Journal:  AAPS PharmSciTech       Date:  2018-11-12       Impact factor: 3.246

3.  Effect of neat and binary vehicle systems on the solubility and cutaneous delivery of piperine.

Authors:  Abdullah Hasan Alomrani; Faisal Ibraheem Alhazza; Khalid Mohammed AlGhamdi; Gamal Mohamed El Maghraby
Journal:  Saudi Pharm J       Date:  2017-12-18       Impact factor: 4.330

4.  Formulation Development for Transdermal Delivery of Raloxifene, a Chemoprophylactic Agent against Breast Cancer.

Authors:  Deepal Vora; Amruta Dandekar; Sonalika Bhattaccharjee; Onkar N Singh; Vivek Agrahari; M Melissa Peet; Gustavo F Doncel; Ajay K Banga
Journal:  Pharmaceutics       Date:  2022-03-20       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.